Please login to the form below

Not currently logged in
Email:
Password:

fasinumab

This page shows the latest fasinumab news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

Among numerous rivals, Regeneron was forced to halted high dose treatment of its contender fasinumab following a risk-benefit assessment conducted by an Independent Data Monitoring Committee.

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    4, 325. Regeneron / Teva. Licence. Fasinumab in P3 for osteoarthritis pain, upfront payment $250m [excludes rights to Japan, Korea and other Asian markets].

  • Deal Watch October 2015 Deal Watch October 2015

    Collaboration, option to license. 339. Regeneron Pharmaceuticals/ Mitsubishi Tanabe Pharma. Fasinumab (REGN475), nerve growth factor mAb for musculoskeletal pain (p2b).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics